Menu
Search
|

Menu

Close
X

Merrimack Pharmaceuticals Inc MACK.OQ (NASDAQ Stock Exchange Global Market)

7.18 USD
-- (--)
As of Mar 19
chart
Previous Close 7.18
Open --
Volume --
3m Avg Volume 12,502
Today’s High --
Today’s Low --
52 Week High 10.51
52 Week Low 3.35
Shares Outstanding (mil) 13.34
Market Capitalization (mil) 95.80
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

No Data Available
Sell Hold Buy

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
EPS (USD)
FY18
-4.547
FY17
-4.182
FY16
-12.369
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
58.80
Price to Sales (TTM)
vs sector
--
8.99
Price to Book (MRQ)
vs sector
1.63
4.66
Price to Cash Flow (TTM)
vs sector
--
40.60
Total Debt to Equity (MRQ)
vs sector
25.29
17.49
LT Debt to Equity (MRQ)
vs sector
25.29
13.83
Return on Investment (TTM)
vs sector
-70.83
12.11
Return on Equity (TTM)
vs sector
-78.23
13.22

EXECUTIVE LEADERSHIP

Gary Crocker
Chairman of the Board, Since 2017
Salary: --
Bonus: --
Richard Peters
President, Chief Executive Officer, Director, Since 2017
Salary: --
Bonus: --
Jean Franchi
Chief Financial Officer,Principal Financial Officer, Principal Accounting Officer, Treasurer, Since 2017
Salary: --
Bonus: --
John Green
Controller, Since 2017
Salary: --
Bonus: --
Ellen Forest
Head of Human Resources, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

1 Kendall Sq Ste B7201
CAMBRIDGE   MA   02139-1670

Phone: +1617.4411000

Merrimack Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in designing novel treatments for cancer by targeting biomarker-defined cancers. Its clinical programs include MM-121 (seribantumab), MM-141 (istiratumab) and MM-310. MM-121 is a fully human monoclonal antibody that binds to the ErbB3 (HER3) receptor and targets heregulin positive cancers. MM-141 is a fully human tetravalent bispecific antibody designed to block tumor survival signals by targeting receptor complexes containing the insulin-like growth factor 1, or IGF-1, receptor and ErbB3 (HER3) cell surface receptor. MM-310 is an antibody-directed nanotherapeutic that targets the ephrin receptor A2, or EphA2, receptor and contains a novel prodrug of the highly potent chemotherapy docetaxel. The Company’s preclinical programs include MM-161, ATRi, BCL2/BCLxl, TRAIL, Immuno-oncology and STIMULI.

SPONSORED STORIES